Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: A multicenter phase II study

Cancer Investigation

Volumn 23, Issue 1, 2005, Pages 9-12

  Androulakis, Nikolaos ^a   Syrigos, Konstantinos ^b   Polyzos, Aristidis ^c   Aravantinos, Gerasimos ^d   Stathopoulos, George P ^e   Ziras, Nikolaos ^f   Mallas, Konstantinos ^a   Vamvakas, Lambros ^a   Georgoulis, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Sismanogllon General Hosptial of Athens   (Greece)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d Agii Anargyri Anticancer Hospital of Athens   (Greece)

^e IASO GENERAL HOSPITAL   (Greece)

^f METAXA CANCER HOSPITAL   (Greece)

Author keywords

Oxaliplatin; Pancreatic Cancer; Phase II Study

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INOPERABLE CANCER; MALE; METASTASIS; MULTICENTER STUDY; NEUROTOXICITY; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; VOMITING;

EID: 14844320515     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1081/CNV-46502     Document Type: Article

References (24)

1. Tominaga, S.; Kuroishi, T. Epidemiology of pancreatic cancer. Sem. Surg. Oncol. 1998, 15, 3-7.
2. Barkin, J.S.; Goldstein, J.A. Diagnostic and therapeutic approach to pancreatic cancer. Biomed. Pharmacother. 2000, 54, 400-409.
3. Hawes, R.H.; Xiong, Q.; Waxman. I.; Chang, K.J.; Evans, D.B.; Abbruzzese, J.L. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am. J. Gastroenterol. 2000, 95, 17-31.
4. Burris, H.A.; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; Von Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
5. Glimelius, B.; Huffman, K.; Sjoeden, P.O.; Jacobsson, G.; Selistrom, H.; Enander, L.K.; Linne, T.; Svensson, C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 1996, 7, 593-600.
6. Palmer, K.R.; Kerr, M.; Knowles, G.; Cull, A.; Carter, D.C.; Leonard. R.C. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg. 1994, 8, 882-885.
7. Raymond, E.; Lawrence, R.; Izbicka, E.; Faivre, S.; Von Hoff, D.D. Activity of oxaliplatin against human tumour colony-forming units. Clin. Cancer Res. 1998, 4, 1021-1029.
8. Kornmann, M.; Fakler, H.; Butzer, U.; Beger, H.G.; Link, K.H. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res. 2000, 20, 3259-3264.
9. Rougier, P.; Ducreux, M.; Kaci, M.O.; Boige, V.; Mitry, E.; Seitz, J.F.; Bugat, R.; Breau, J.L.; Etienne, P.L.; Bouche, O.; Cvitkovic, E.; Bexon, A. Randomized phase III study of oxaliplatin alone (OXA), 5-fluorouracil (5-FU) alone, and the two drugs combined (OXA_Fu) in advanced or metastatic pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 2000, 19, 262a.
10. Fink, D.; Nebel, S.; Aebi, S.; Zheng, H.; Cenni, B.; Nehme, A.; Christen, R.D.; Howell, S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56, 4881-4886.
11. Brentnall, T.A.; Chen, R.; Lee, J.G.; Kimmey, M.B.; Bronner, M.P.; Haggitt, R.C.; Kowdley. K.V.; Hecker, L.M.; Byrd, D.R. Microsatellite instability and k-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res. 1995, 55, 4264-4267.
12. National Cancer Institute. Guidelines for Reporting Adverse Drug Reactions; Division of Cancer Treatment, National Cancer Institute: Bethesda, MD, 1978.
13. World Health Organization. Handbook for Reporting Results of Cancer Treatment; WHO Offset Publication No. 48, World Health Organization: Geneva, 1979.
14. Fleming, T. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38, 143-152.
15. Klein, B.; Sadikov, E.; Mishaeli, M.; Levin, I.; Fige, A. Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer. Oncol. Rep. 2000, 7, 875-877.
16. Louvet, C.; Andre, T.; Lledo, G.; Hammel, P.; Bleiberg. H.; Bouleuc, C.; Gamelin, E.; Flesch, M.; Cvitkovic, E.; de Gramont, A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J. Clin. Oncol. 2002, 20, 1518-1521.
17. Garnier, C.; Rebischung, C.; Chirpaz, E.; Baioso, J.; Fournet, J.; Pasquier, D.; Khayat, D.; Esterni, J.; Schaerer, R.; Mousseau, M. Phase II study of a combination with leucovorin (LV), 5-FU bolus and infusion (FU), gemcitabine (GEM) and oxaliplatin (L-OHP) (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc. Am. Soc. Clin. Oncol. 2001, 20, 156a.
18. Alberts, S.R.; Townley, P.M.; Goldberg, R.M.; Cha, S.S.; Moore, D.F., Jr.; Krook, J.E.; Pitot, H.C.; Fitch, T.R.; Wiesenfeld, M.; Mailliard, J.A.; Sargent, D.J. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Ann. Oncol. 2002. 13, 553-557.
19. Conroy, T.; Paillot, B.; Francois, E.; Rixe, O.; Bugat, R.; Jacob, J.H.; Metges, J.P.; Nasca, S.; Hua, A. Irinotecan (CPT-II), oxaliplatin (L-OHP), plus 5-FU/leucovorin (5-FU/LV) as first-line chemotherapy in patients (pts) with advanced pancreatic adenocarcinoma (APA). Proc. Am. Soc. Clin. Oncol. 2002, 21, 147a.
20. Pelzer, U.; Hempel, C.; Stieler, J.; Köneke, D.; Riess, H.; Oettle, H. Oxaliplatin (OXA) in combination with high dose 5-FU (24 h)/folinic acid (FA) as salvage therapy in patients with gemzar-refractory advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2002, 21, 172a.
21. Cantore, M.; Rabbi, C.; Cavazzini, G.; Ogliani, C.; Aitini, E. Irinotecan and oxaliplatin combination therapy in patients with advanced pretreated pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2002, 21, 96b.
22. Faivre, S.; Raymond, E.; Woynarowski, J.M.; Cvitkovic, E. Suppraadditive effect of 2′2′-diflurodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother. Pharmacol. 1999, 44, 117-123.
23. Raymond, E.; Buguet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic. E.; Allain, P.; Louvet, C.; Gespach, C. Antitumour activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancer. Anticancer Drugs 1997, 8, 876-885.
24. Van Cutsem, E.; Karasek, P.; Oettle, H.; Vervenne, A.; Szawlowski, P.; Schoffski, S.; Post, H.; Neumann, H.; Safran, Y.; Humblet, H.; van de Velde, Y.; Ma, D. Phase III trial comparing gemcitabine + RI 15777 (Zarnestra) versus gemcitabine+ placebo in advanced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. 2002, 21, 130a.